2018
Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3
Doyle HA, Koski RA, Bonafé N, Bruck RA, Tagliatela SM, Gee RJ, Mamula MJ. Epidermal growth factor receptor peptide vaccination induces cross-reactive immunity to human EGFR, HER2, and HER3. Cancer Immunology, Immunotherapy 2018, 67: 1559-1569. PMID: 30056598, PMCID: PMC7268894, DOI: 10.1007/s00262-018-2218-9.Peer-Reviewed Original ResearchConceptsAntibody-dependent cell-mediated cytotoxicityEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody treatmentAntibody treatmentImmune serumElicit anti-tumor immunityAnti-EGFR monoclonal antibodiesHuman epidermal growth factor receptorPeptide-based vaccinationCross-reactive immunityT cell responsesCell-mediated cytotoxicityAnti-tumor antibodiesNatural anti-tumor antibodiesMDA-MB-453Tumor cell killingErbB family membersGrowth factor receptorPeptide vaccinationStandard chemotherapyImmune toleranceCurrent treatmentDrug infusionRadiation therapy
2006
Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity*
Doyle HA, Zhou J, Wolff MJ, Harvey BP, Roman RM, Gee RJ, Koski RA, Mamula MJ. Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity*. Journal Of Biological Chemistry 2006, 281: 32676-32683. PMID: 16950786, DOI: 10.1074/jbc.m604847200.Peer-Reviewed Original ResearchConceptsTRP-2 peptideImmune toleranceT cellsNormal immune tolerancePeptide-pulsed targetsPeptide-immunized miceCytotoxic T lymphocytesB cell toleranceStrong immune responseTetramer analysisLymphocyte immunityMelanoma antigensT lymphocytesImmune responseCell toleranceImmune systemPost-translational protein modificationTyrosinase-related proteinCD8AntigenTumor proteinCellsImmunizationLymphocytesMice